
Commentary|Podcasts|March 29, 2024
A Further Examination of Pharmacy Benefit Managers
Author(s)Nicholas Saraceno, Senior Editor
Brandon Newman joins The Pharmaceutical Commerce Podcast to discuss the evolving role of PBMs, including the importance of drug price transparency.
Advertisement
In this exclusive PC Podcast interview, Brandon Newman, Xevant’s CEO and founder, explores:
- The implications of the Inflation Reduction Act’s price negotiation provisions, and how these could result in ripple effects across the healthcare system
- The role that pharmacy benefit managers (PBMs) and other intermediaries' play when it comes to determining drug costs, and how spread pricing is involved
- How Xevant helps improve drug cost transparency efforts
- Strategies for affordability Newman would offer the pharma industry that can be implemented immediately
The latest episode of The Pharmaceutical Commerce Podcast is available directly on
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Q&A: Scoring Drug Supply Chains for Resilience, Not Just Price
2
Why Onshoring Alone Won't Secure Pharma Supply Chains
3
FAQ: Pharma's July 31 Tariff Deadline Has Passed. Now What?
4
The 2026 Forecast Revisited: Dealmaking, Direct-to-Patient and Patient Affordability
5




